NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
9
Mechanism of Action
Mitogen-Activated Protein Kinase Kinase 1 Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
Started Dec 2025
36 enrolled
HealthyVolunteer
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Started May 2025
32 enrolled
HealthyHepatic Impairment
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Started Feb 2025
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Started Feb 2024
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Started Feb 2023
23 enrolled
Advanced Solid Tumor
Loss of Exclusivity
LOE Date
Oct 10, 2044
226 months away
Patent Expiry
Oct 10, 2044
Exclusivity Expiry
Feb 11, 2032